NCT00037583View on ClinicalTrials.gov

Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

Not specified

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Gemtuzumab Ozogamicin

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00037583 - Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter